Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

BACKGROUND: Iruplinalkib (WX-0593) is an anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor. Here we reported the single-arm, phase II study (INTELLECT) results of the efficacy and safety of iruplinalkib for ALK-positive crizotinib-resistant advanced non-small cell lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Chen, Jianhua, Zhang, Helong, Zhang, Zhihong, Zhang, Yiping, Wang, Zhehai, Zhang, Shucai, Zhao, Jian, Liu, Chunling, Wang, Xiuwen, Zhao, Yanqiu, Hu, Changlu, Yang, Lei, Hao, Xuezhi, Wang, Lin, Liu, Yunpeng, Yu, Yan, Zhao, Jun, Wang, Mengzhao, Zhang, Liangming, Sun, Sanyuan, Hu, Yanping, Gu, Kangsheng, Hang, Xiaosheng, Shan, Jinlu, Zhang, Yu, Tan, Bangxian, Yang, Weihua, Yang, Runxiang, Si, Meimei, Geng, Huaize, Li, Hui, Kang, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960473/
https://www.ncbi.nlm.nih.gov/pubmed/36829154
http://dx.doi.org/10.1186/s12916-023-02738-5

Ejemplares similares

Ejemplares similares